CN102460152B - 通过测量Her-3确定患者反应的方法 - Google Patents

通过测量Her-3确定患者反应的方法 Download PDF

Info

Publication number
CN102460152B
CN102460152B CN201080009543.XA CN201080009543A CN102460152B CN 102460152 B CN102460152 B CN 102460152B CN 201080009543 A CN201080009543 A CN 201080009543A CN 102460152 B CN102460152 B CN 102460152B
Authority
CN
China
Prior art keywords
sample
purposes
antibody
amount
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080009543.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102460152A (zh
Inventor
M·贝茨
J·W·库克
G·迪德里希
L·古德曼
A·慕克吉
G·帕里
J·斯珀林德
S·J·威廉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Labcorp Holdings Inc
Original Assignee
Laboratory Corp of America Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratory Corp of America Holdings filed Critical Laboratory Corp of America Holdings
Publication of CN102460152A publication Critical patent/CN102460152A/zh
Application granted granted Critical
Publication of CN102460152B publication Critical patent/CN102460152B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201080009543.XA 2009-01-15 2010-01-15 通过测量Her-3确定患者反应的方法 Expired - Fee Related CN102460152B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14502909P 2009-01-15 2009-01-15
US61/145,029 2009-01-15
US17663009P 2009-05-08 2009-05-08
US61/176,630 2009-05-08
US18796209P 2009-06-17 2009-06-17
US61/187,962 2009-06-17
PCT/US2010/021281 WO2010083470A1 (en) 2009-01-15 2010-01-15 Methods of determining patient response by measurement of her-3

Publications (2)

Publication Number Publication Date
CN102460152A CN102460152A (zh) 2012-05-16
CN102460152B true CN102460152B (zh) 2014-11-26

Family

ID=42340114

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080009543.XA Expired - Fee Related CN102460152B (zh) 2009-01-15 2010-01-15 通过测量Her-3确定患者反应的方法

Country Status (12)

Country Link
US (4) US8349574B2 (https=)
EP (1) EP2387711B1 (https=)
JP (1) JP5746051B2 (https=)
KR (1) KR20110120891A (https=)
CN (1) CN102460152B (https=)
AU (1) AU2010204583A1 (https=)
BR (1) BRPI1007321A2 (https=)
CA (1) CA2749846C (https=)
ES (1) ES2535723T3 (https=)
IL (1) IL214072A (https=)
SG (2) SG172983A1 (https=)
WO (1) WO2010083470A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
CN101679974B (zh) 2007-03-27 2015-09-30 航道生物技术有限责任公司 包含抗体替代轻链序列的构建体和文库
US8357277B2 (en) 2007-11-27 2013-01-22 Laboratory Corp. of America Holdings Enhanced method for detecting and/or quantifying an analyte in a sample
EP2235536A4 (en) * 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
ES2637411T3 (es) 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
US20120295259A1 (en) * 2011-05-19 2012-11-22 Laboratory Corporation Of America Holdings Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
US11401344B2 (en) 2008-12-01 2022-08-02 Laboratory Corporation Of America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
JP2012515353A (ja) * 2009-01-15 2012-07-05 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ−２発現の測定による患者の反応を判定する方法
EP2387711B1 (en) 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-3
CA2761681A1 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
NZ596468A (en) * 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
WO2011047087A2 (en) 2009-10-13 2011-04-21 Nanostring Technologies, Inc. Protein detection via nanoreporters
RS54795B1 (sr) 2009-12-22 2016-10-31 Roche Glycart Ag Anti-her3 antitela i njihova korišćenja
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US8679767B2 (en) * 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
EP2736928B1 (en) * 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2014159662A1 (en) 2013-03-13 2014-10-02 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
US12558316B2 (en) 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
US20160041171A1 (en) * 2013-04-05 2016-02-11 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
CA2924386C (en) * 2013-10-04 2021-07-20 F. Hoffmann-La Roche Ag Antibodies specifically binding to her3
WO2015130173A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
JP6771385B2 (ja) 2014-02-28 2020-10-21 メルス ナムローゼ フェンノートシャップ 二重特異性抗体および医薬組成物
SG10202107053QA (en) 2015-07-17 2021-08-30 Nanostring Technologies Inc Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue
WO2017015097A1 (en) 2015-07-17 2017-01-26 Nanostring Technologies, Inc. Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue
SMT202100230T1 (it) 2015-10-23 2021-07-12 Fundacio Inst De Recerca Biomedica Irb Barcelona Molecole di legame che inibiscono la crescita tumorale
WO2017161030A1 (en) 2016-03-15 2017-09-21 Laboratory Corporation Of America Holdings Methods of assessing protein interactions between cells
MX2019011658A (es) 2017-03-31 2019-11-18 Merus Nv Agente que se dirige al receptor 2 del factor de crecimiento epidermico humano (erbb-2) y anticuerpo biespecifico con sitios de union a antigeno que se unen a un epitopo sobre una parte extracelular de erbb-2 y el receptor 3 del factor de crecimiento epidermico humano (erbb-3), para el tratamiento de un individuo con un tumor positivo para erbb-2, erbb-2/erbb-3.
IL269656B2 (en) 2017-03-31 2024-06-01 Merus Nv Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
US20190249248A1 (en) 2018-02-12 2019-08-15 Nanostring Technologies, Inc. Biomolecular probes and methods of detecting gene and protein expression

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480968A (en) * 1989-12-01 1996-01-02 The United States Of America As Represented By The Department Of Health And Human Services Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto
WO2005011607A2 (en) * 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
CN1639192A (zh) * 2002-02-26 2005-07-13 希格马托制药工业公司 抗人腱生蛋白单克隆抗体
CN101115836A (zh) * 2005-02-09 2008-01-30 健泰科生物技术公司 用基质金属蛋白酶拮抗剂抑制her2脱落
WO2008145338A2 (en) * 2007-05-29 2008-12-04 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5117165B1 (https=) 1973-12-27 1976-05-31
US4318846A (en) 1979-09-07 1982-03-09 Syva Company Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
WO1989012232A1 (en) 1988-06-08 1989-12-14 London Diagnostics, Inc. Assays utilizing sensitizer-induced production of detectable signals
ES2094795T3 (es) 1990-11-02 1997-02-01 Ici Plc Ftalocianinas polisustituidas.
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5340716A (en) 1991-06-20 1994-08-23 Snytex (U.S.A.) Inc. Assay method utilizing photoactivated chemiluminescent label
US5578498A (en) 1991-05-22 1996-11-26 Behringwerke Ag Metal chelate containing compositions for use in chemiluminescent assays
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
CA2141451C (en) 1992-07-31 2003-10-07 John S. Pease Photoactivatable chemiluminescent matrices
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
AU707440B2 (en) * 1994-03-29 1999-07-08 Celltech Therapeutics Limited Antibodies against E-selectin
US5986076A (en) 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
SE9601676D0 (sv) 1996-04-30 1996-04-30 Ulf Landegren Improved probing of specific mucleic acids
US5945526A (en) 1996-05-03 1999-08-31 Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US5763602A (en) 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US6001673A (en) 1999-02-11 1999-12-14 Ericsson Inc. Methods for packaging integrated circuit devices including cavities adjacent active regions
US6514700B1 (en) 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
US6682887B1 (en) * 1999-04-30 2004-01-27 Aclara Biosciences, Inc. Detection using degradation of a tagged sequence
US20040248150A1 (en) 1999-04-02 2004-12-09 Sharat Singh Methods employing oligonucleotide-binding e-tag probes
US6322980B1 (en) * 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6627400B1 (en) * 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US20030235832A1 (en) 2000-06-21 2003-12-25 Ahmed Chenna Multiplexed analysis by chromatographic separation of molecular tags
US7001725B2 (en) * 1999-04-30 2006-02-21 Aclara Biosciences, Inc. Kits employing generalized target-binding e-tag probes
US7037654B2 (en) * 1999-04-30 2006-05-02 Aclara Biosciences, Inc. Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents
US6673550B2 (en) * 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US6649351B2 (en) * 1999-04-30 2003-11-18 Aclara Biosciences, Inc. Methods for detecting a plurality of analytes by mass spectrometry
US20030092012A1 (en) 2001-11-09 2003-05-15 Ahmed Chenna Methods for detecting a plurality of analytes by chromatography
DE60040981D1 (de) 1999-05-14 2009-01-15 Genentech Inc BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
KR20110008112A (ko) 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
ATE271691T1 (de) * 2000-01-12 2004-08-15 Ventana Med Syst Inc Verfahren zum nachweis der effektivität einer krebstherapie
US7306904B2 (en) 2000-02-18 2007-12-11 Olink Ab Methods and kits for proximity probing
MY133839A (en) 2000-03-14 2007-11-30 Shell Int Research Process for the carbonylation of pentenenitrile
GB0007911D0 (en) 2000-03-30 2000-05-17 Novartis Ag Organic compounds
US7160735B2 (en) 2000-04-28 2007-01-09 Monogram Biosciences, Inc. Tagged microparticle compositions and methods
US7771929B2 (en) 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
US20040067498A1 (en) 2000-04-28 2004-04-08 Ahmed Chenna Detection of nucleic acid sequences by cleavage and separation of tag-containing structures
US20030207300A1 (en) 2000-04-28 2003-11-06 Matray Tracy J. Multiplex analytical platform using molecular tags
US20030170734A1 (en) 2000-04-28 2003-09-11 Stephen Williams Multiplexed assays using electrophoretically separated molecular tags
US7537938B2 (en) 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
EP1305632B1 (en) 2000-05-04 2011-07-27 Siemens Healthcare Diagnostics Products GmbH Methods for detection of multiple analytes
US6547654B2 (en) 2000-07-22 2003-04-15 Americo Del Raso Automatic abrasive sleeve tightening means and quick release system for an oscillating spindle sander
US6630296B2 (en) * 2000-08-08 2003-10-07 Aclara Biosciences, Inc. Multiplexed enzymatic assays
AU2001280222A1 (en) 2000-08-19 2002-03-04 Sung-Cheol Kim Communication line separator
EP1236740B1 (de) 2001-02-28 2012-07-18 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
US7041459B2 (en) * 2001-05-21 2006-05-09 Monogram Biosciences, Inc. Analyzing phosphorylated proteins
CA2445053A1 (en) 2001-05-21 2002-11-28 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
WO2002097112A2 (en) 2001-05-26 2002-12-05 Aclara Biosciences, Inc. Catalytic amplification of multiplexed assay signals
AU2002316577A1 (en) 2001-07-09 2003-01-29 Aclara Biosciences, Inc. Cell-screening assay and composition
WO2003055439A2 (en) 2001-07-18 2003-07-10 The Regents Of The University Of California Her2/neu target antigen and use of same to stimulate an immune response
US20040241688A1 (en) 2001-07-19 2004-12-02 Cuneyt Bukusoglu Human tissue specific drug screening procedure
GB2378245A (en) 2001-08-03 2003-02-05 Mats Nilsson Nucleic acid amplification method
EP1414496B1 (en) 2001-08-07 2010-10-20 Galephar M/F Pharmaceutical composition containing a combinaition of ppar-alpha, pravastatin and polyglycolized glyceride
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
US20050043820A1 (en) 2001-10-12 2005-02-24 James Browning Biomaterial comprising microfeatures
WO2003033741A1 (en) 2001-10-16 2003-04-24 Aclara Biosciences, Inc. Universal e-tag primer and probe compositions and methods
US7045311B2 (en) * 2001-10-25 2006-05-16 Monogram Biosciences, Inc. Whole cell assay systems for cell surface proteases
WO2003042657A2 (en) 2001-11-09 2003-05-22 Aclara Biosciences Inc. Detection of nucleic acid sequences by cleavage and separation of tag-containing structures
WO2003042658A2 (en) 2001-11-09 2003-05-22 Aclara Biosciences, Inc. Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents
JP2005509859A (ja) 2001-11-09 2005-04-14 アクララ バイオサイエンシーズ， インコーポレイテッド タグ標識された微粒子組成物および方法
WO2003051669A1 (en) 2001-12-18 2003-06-26 Aclara Biosciences, Inc. Photoactivation device and method
US7135174B2 (en) * 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
JP2006509183A (ja) 2002-03-05 2006-03-16 アクララ バイオサイエンシーズ， インコーポレイテッド 膜結合増感剤を用いる多重分析
ES2374311T3 (es) 2002-03-13 2012-02-15 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados.
JP2005521885A (ja) 2002-04-02 2005-07-21 アクララ バイオサイエンシーズ， インコーポレイテッド 電気泳動的に分離される分子タグを使用する多重化アッセイ
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20040229293A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui Surface receptor complexes as biomarkers
US20090111127A1 (en) 2002-05-21 2009-04-30 Monogram Biosciences Inc. Surface Receptor Complexes as Biomarkers
US20040229299A1 (en) 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040175765A1 (en) 2002-07-05 2004-09-09 Sharat Singh Cell-screening assay and composition
WO2004008099A2 (en) * 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
JP4443407B2 (ja) 2002-07-25 2010-03-31 アクララ バイオサイエンシーズ， インコーポレイテッド レセプターオリゴマー形成の検出
CA2493671A1 (en) 2002-07-26 2004-02-05 Aclara Biosciences, Inc. Lipophilic electrophoretic probes
US20040091850A1 (en) 2002-11-08 2004-05-13 Travis Boone Single cell analysis of membrane molecules
EP1573061A4 (en) 2002-12-18 2006-03-08 Aclara Biosciences Inc MULTIPLEX IMMUNOHISTOCHEMICAL TESTS USING MOLECULAR MARKERS
EP1599492A4 (en) 2003-01-17 2008-09-24 Virologic Inc RECIPIENTS DORPHANIZATION BY USING MARKED MOLECULAR LIBRARIES
EP1613205B1 (en) 2003-04-01 2013-04-24 Monogram BioSciences, Inc. Erbb surface receptor complexes as biomarkers
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
US20100291594A1 (en) 2003-07-17 2010-11-18 Laboratory Corporation Of America Holdings ErbB Surface Receptor Complexes as Biomarkers
EP1673399B1 (en) 2003-08-11 2017-04-05 Monogram BioSciences, Inc. Detecting and profiling molecular complexes
EP1664716A4 (en) 2003-08-15 2008-08-13 Smithkline Beecham Corp CANCER BIOMARKERS
US20050106571A1 (en) 2003-10-02 2005-05-19 The Regents Of The University Of California Mammalian T1R3 sweet taste receptors
US7402399B2 (en) * 2003-10-14 2008-07-22 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
CA2543830A1 (en) 2003-10-27 2005-05-19 Monogram Biosciences, Inc. Detecting human anti-therapeutic antibodies
SI1674111T1 (sl) * 2004-07-09 2011-02-28 Chugai Pharmaceutical Co Ltd Protitelo proti glipikanu 3
WO2006044748A2 (en) 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
DK1842226T3 (da) 2004-11-03 2010-10-18 Iris Molecular Diagnostics Inc Homogen analytpåvisning
US7939267B2 (en) 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
US7862995B2 (en) * 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
WO2006068640A1 (en) * 2004-12-21 2006-06-29 Cell Signaling Technology, Inc. Protein phosphorylation in egfr-signaling pathways
WO2006084018A2 (en) 2005-02-02 2006-08-10 Monogram Biosciences, Inc. Methods for determining responsiveness to cancer therapy
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
WO2006133460A2 (en) * 2005-06-09 2006-12-14 Yale University Methods for diagnosing and treating breast cancer based on a her/er ratio
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
CN1928563B (zh) 2005-09-09 2010-04-28 上海张江生物技术有限公司 乳腺癌的免疫组化诊断试剂盒和测试片
WO2007041502A2 (en) * 2005-09-30 2007-04-12 Monogram Biosciences Methods for determining responsiveness to cancer therapy
EP2049568A2 (en) 2006-04-07 2009-04-22 Københavns Universitet Erbb receptor-derived peptide fragments
JP5117165B2 (ja) 2007-11-09 2013-01-09 花王株式会社 水中油型乳化組成物の製造方法
US8357277B2 (en) 2007-11-27 2013-01-22 Laboratory Corp. of America Holdings Enhanced method for detecting and/or quantifying an analyte in a sample
CN101230390A (zh) 2007-12-07 2008-07-30 湖北大学 一种用于妇科恶性肿瘤早期筛选的基因芯片及其检测方法
EP2235536A4 (en) 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
ES2342646B1 (es) 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
ES2637411T3 (es) 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
JP2012515353A (ja) 2009-01-15 2012-07-05 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ−２発現の測定による患者の反応を判定する方法
EP2387711B1 (en) 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-3

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480968A (en) * 1989-12-01 1996-01-02 The United States Of America As Represented By The Department Of Health And Human Services Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto
CN1639192A (zh) * 2002-02-26 2005-07-13 希格马托制药工业公司 抗人腱生蛋白单克隆抗体
WO2005011607A2 (en) * 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
CN101115836A (zh) * 2005-02-09 2008-01-30 健泰科生物技术公司 用基质金属蛋白酶拮抗剂抑制her2脱落
WO2008145338A2 (en) * 2007-05-29 2008-12-04 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Development of highly quantitative, sensitive, and reproducible immunoassays for the detection of EGFR/HER1 and ErbB3/HER3 in formalin-fixed, paraffin-embedded (FFPE) tumor tissue;Shi Y et al.;《European Journal of Cancer》;20081001;第6卷(第12期);34-35 *
双重酪氨酸激酶抑制剂Lapatinib治疗乳腺癌研究进展;陆宁;《国际肿瘤学杂志》;20070531;第34卷(第5期);362-365 *

Also Published As

Publication number Publication date
AU2010204583A2 (en) 2011-09-01
ES2535723T3 (es) 2015-05-14
BRPI1007321A2 (en) 2018-07-10
KR20110120891A (ko) 2011-11-04
IL214072A (en) 2016-08-31
US20180164319A1 (en) 2018-06-14
AU2010204583A1 (en) 2011-08-25
JP5746051B2 (ja) 2015-07-08
EP2387711A1 (en) 2011-11-23
JP2012515226A (ja) 2012-07-05
US9110066B2 (en) 2015-08-18
US8349574B2 (en) 2013-01-08
EP2387711A4 (en) 2012-07-18
US20100210034A1 (en) 2010-08-19
CN102460152A (zh) 2012-05-16
WO2010083470A1 (en) 2010-07-22
CA2749846A1 (en) 2010-07-22
SG172983A1 (en) 2011-08-29
EP2387711B1 (en) 2015-04-22
IL214072A0 (en) 2011-08-31
US20160061839A1 (en) 2016-03-03
CA2749846C (en) 2018-08-07
US10775382B2 (en) 2020-09-15
SG10201408392PA (en) 2015-01-29
US9766242B2 (en) 2017-09-19
US20130071859A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
CN102460152B (zh) 通过测量Her-3确定患者反应的方法
US10273308B2 (en) Methods of producing antibodies specific for p95
CN102439452B (zh) 通过测量her-2表达确定患者应答的方法
US10416162B2 (en) Her2 diagnostic methods
JP2017138334A (ja) 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法
Mudgal et al. Detecting human epidermal growth factor receptor 2 (HER2) amplification: Proof of concept of an alternative approach

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141126